

Supplementary Note 1-11:

Supplementary Note 1A: *Characterizing newly defined cis-pQTLs within European and African ancestries*

 To verify that newly defined *cis*-pQTLs were comparable, we assessed the within-ancestry concordance of *cis*-pQTL effect sizes in European (**Supplementary Figure 1a**) and in African ancestries (**Supplementary Figure 1b**). We found high concordance of effects suggesting that within each ancestry, the newly defined *cis*-pQTLs are comparable.

-
- Methods**:**

 We assessed the within-ancestry concordance between European ancestry proteomics cohorts by aligning the effect allele of *cis*-pQTLs in each cohort to the minor allele in the UKB 50k 102 reference panel. Similarly, when comparing the within-ancestry concordance between African
103 ancestry proteomics cohorts, we first alianed effect alleles of *cis-*pQTLs in each cohort to the ancestry proteomics cohorts, we first aligned effect alleles of *cis-*pQTLs in each cohort to the

- minor allele of the corresponding variant in the African ancestry HGDP+1kGP reference panel.
-
-

Supplementary Note 1B: *Further details on defining "strict variant-to-gene" (strict V2G)*

- *cis-pQTLs*
- 109
110

 Upon defining *cis*-pQTLs in each cohort, we performed two additional steps to select genetic instruments which we term strict V2G *cis-pQTLs*.

- First, to minimize potential horizontal pleiotropic effects, we removed *cis*-variants associated with two or more protein-coding genes (**Supplementary Note Table 1**), thus retaining *cis*-pQTLs associated with a single protein-coding gene, which we term "strict" *cis*-pQTLs.
-

117 Second, we leveraged multiple sources of evidence to assign variants to genes using Open
118 Targets Genetics V2G score. As expected, upon performing strict V2G filtering within each cohort, 118 Targets Genetics V2G score. As expected, upon performing strict V2G filtering within each cohort,
119 we found that strict V2G *cis*-pQTLs had a larger proportion of proteins with a single associated we found that strict V2G *cis-*pQTLs had a larger proportion of proteins with a single associated *cis*-pQTL compared to all *cis*-pQTLs (**Supplementary Note Table 2**), and the maximum number of *cis*-pQTLs associated with a single protein was either the same or lower across all cohorts in all ancestries (**Supplementary Note Table 3**). The number of strict V2G *cis*-pQTLs for each protein is shown in **Supplementary Note Table 4**. The maximum number of strict V2G *cis*-pQTLs 124 per protein was larger in all European ancestry cohorts compared to African ancestry cohorts and
125 the Kyoto University Nagahama East Asian ancestry cohort (**Supplementary Note Table 3**). For the Kyoto University Nagahama East Asian ancestry cohort (**Supplementary Note Table 3**). For example, the UKB-PPP European ancestry cohort had a range of 1 up to 21 strict V2G *cis*-pQTLs per protein while the number of strict V2G *cis*-pQTLs per protein in the Kyoto University Nagahama East Asian ancestry cohort ranged from 1 to 3.

-
-
- **Supplementary Note 1C:** *Further details on instrumentable proteins in each cohort*
-

 In European ancestries, we identified 1,485 instruments for 1,102 proteins for ARIC (*n* = 7,213; **Supplementary Table 2**), 2,083 instruments for 1,243 proteins for deCODE (*n* = 35,559; **Supplementary Table 3**), 1,637 instruments for 1,194 proteins for Fenland ($n = 10,708$; **Supplementary Table 4**), and 2,194 instruments for 1,292 proteins for UKB-PPP (*n* = 34,557; **Supplementary Table 5**). In African ancestries, we identified 1,080 instruments for 877 proteins for ARIC (*n* = 1,871; **Supplementary Table 6**), and 604 instruments for 554 proteins for UKB-

 PPP (*n* = 931; **Supplementary Table 7**). Finally, in the Kyoto University Nagahama East Asian ancestry cohort, 663 instruments were identified from 602 proteins (*n* = 1,823; **Supplementary Table 8**).

 We also assessed whether any instrumentable proteins were shared across cohorts within European and African ancestries. Here, we use proteins to refer to the protein-coding gene name in order to avoid double counting SomaScan v4 aptamers and to enable harmonization with Olink assays. Protein-coding genes were quantified based on Ensembl gene IDs. Within European ancestries, 434 proteins were shared across all fours cohorts while 375 were unique to the ARIC, 148 deCODE, and Fenland cohorts measured with the SomaScan v4 platform, and 652 were unique
149 to the UKB-PPP cohort which measured proteins using Olink Explore 3072 (**Extended Data Fig.** to the UKB-PPP cohort which measured proteins using Olink Explore 3072 (**Extended Data Fig. 4a**), highlighting the value of using two proteomics platforms. In African ancestries, 259 proteins 151 were jointly instrumentable by the ARIC and UKB-PPP cohorts while 591 were unique to ARIC 151 were jointly instrumentable by the ARIC and UKB-PPP cohorts while 591 were unique to ARIC
152 and 294 to UKB-PPP (**Extended Data Fig. 4b**) which emphasizes the value of having two cohorts and 294 to UKB-PPP (**Extended Data Fig. 4b**) which emphasizes the value of having two cohorts from two separate proteomics platforms. The Kyoto University Nagahama East Asian cohort (*n* = 1,823) was able to instrument 581 proteins (**Extended Data Fig. 4c**).

Supplementary Note 2: *Assessing sample overlap in two-sample MR for UK Biobank GWAS outcomes and proteomics cohort*

158 To estimate the extent of bias in two-sample MR causal estimates for European exposures that 159 use proteomics GWAS from the UKB-PPP and European GWAS outcomes that vere generated use proteomics GWAS from the UKB-PPP and European GWAS outcomes that were generated

160 from UK Biobank individuals, we calculated relative bias¹ based on the equation:

161
$$
Relative bias = \phi \times \frac{1}{F}
$$

 The proportion of sample overlap, *ϕ*, ranges between 0 (no sample overlap) and 1 (complete sample overlap), while the F-statistic of the exposure is denoted by *F*. Assessments of sample overlap for the European UKB-PPP and African UKB-PPP proteomics cohorts and corresponding UKB outcomes are shown in **Supplementary Note Table 5**.

167 Since 51 of 179 European GWAS outcomes were based on the UK Biobank, we estimated the 168 extent of potential bias towards the null due to sample overlap in two-sample MR causal estimates extent of potential bias towards the null due to sample overlap in two-sample MR causal estimates for European exposures that used proteomics GWAS from the UKB-PPP (*n* = 34,557). The 170 relative bias¹ when assuming maximum overlap between proteomics GWAS and the 51 UKB outcome GWAS using the minimum F-statistic of 29.8 was estimated to be between 0.250% and 0.769% (**Supplementary Note Table 5**). However, we note that we utilized three additional proteomics cohorts from ARIC, deCODE, and Fenland which may consequently provide further

levels of support for these protein-phenotype associations and mitigate this bias.

Supplementary Note 3: *Cohort level description of putatively causal protein-phenotype pairs in*

European and African ancestry

178 Our analysis involves two different levels of resolution when describing the results. At the ancestry
179 level, this pertains to European, African, and East Asian ancestries. At the cohort level this level, this pertains to European, African, and East Asian ancestries. At the cohort level this involves four cohorts (ARIC, deCODE, Fenland, and UKB-PPP) for European ancestries, two cohorts (ARIC and UKB-PPP) for African ancestries, and the Kyoto University Nagahama cohort for individuals of East Asian ancestry. In the main text, we focus findings at the ancestry level to avoid complicating the results and describe the cohort level details here:

184
185 185 In European ancestries, we identified a total of 6,771 putatively causal protein-phenotype
186 associations (1.764 pairs in ARIC: 1.731 in deCODE, 1.788 in Fenland, and 1.488 in UKB-PPP) associations (1,764 pairs in ARIC; 1,731 in deCODE, 1,788 in Fenland, and 1,488 in UKB-PPP) pertaining to 3,949 unique pairs (**Supplementary Table 14** and **Extended Data Fig. 5a**). In African ancestries, we identified a total of 72 associations involving 35 associations in ARIC and 37 associations in UKB-PPP, with 56 unique protein-phenotype associations across both cohorts involving 28 proteins and 11 phenotypes (**Supplementary Table 15** and **Extended Data Fig. 5b**). The direction of effect was consistent among all common associations between ARIC and UKB-192 PPP including well known proteins known to affect HDL cholesterol such as APOC1, CD36, 1936, 1936 DPEP2, and ITIH4 serving as positive controls.

196 **Supplementary Note 4:** *Proteins involved in a multitude of traits and diseases*

197
198

When quantifying the number of associated phenotypes that each protein was associated with, we found pleiotropic proteins associated with up to 49, 5, and 58 unique phenotypes in European, African, and East Asian ancestries, respectively (**Supplementary Note Table 6**). In European ancestries, 13 proteins were putatively causal for 20 or more outcomes including GCKR, GPN1, BTN3A2, SORT1, RSPO3, HP, RAB21, TIMD4, MST1, APOB, EFEMP1, PCSK9, and PLCG1. 203 Since some phenotype categories had a greater number of outcomes than other categories, we
204 guantified the number of associated phenotype categories each protein was implicated in as well quantified the number of associated phenotype categories each protein was implicated in as well (**Supplementary Note Table 7**). These targets present complex scenarios and may have effects in multiple tissues or organs.

207
208 208 For example, in European ancestries, GCKR (implicated in 10 phenotype categories) increases 209 the risk of type 2 diabetes as previously reported² but our study shows that it also decreases the 210 risk of inflammatory bowel disease (IBD) and cholelithiasis. MST1 (9 phenotype categories) is a
211 macrophage-stimulating protein and hepatocyte growth factor-link protein highly expressed in the macrophage-stimulating protein and hepatocyte growth factor-link protein highly expressed in the 212 liver, suggesting its involvement in immune-related and liver diseases. MST1 has been implicated 213 in IBD³ and its pQTLs have also been found to associate with Crohn's disease, ulcerative colitis, 214 IBD, and primary sclerosing cholangitis (PSC)⁴, a rare liver condition associated with IBD and 215 causing severe liver scarring. We found that increased genetically predicted MST1 levels were 216 protective against IBD, including both Crohn's disease and ulcerative colitis, and PSC. However, 217 despite these protective effects, our results suggest that higher MST1 protein levels may 217 despite these protective effects, our results suggest that higher MST1 protein levels may
218 potentially lead to harmful cardiovascular events, such as increased systolic blood pressure and 218 potentially lead to harmful cardiovascular events, such as increased systolic blood pressure and 219 diastolic blood pressure and a higher risk of coronary artery disease. diastolic blood pressure and a higher risk of coronary artery disease.

220

 In African ancestries, APOA5, APOE, and HP had effects on the most phenotypes with both being associated with 5 outcomes (**Supplementary Note Table 6**). All proteins had effects on 223 phenotypes within a single category aside from ABO and ITIH4 which were causal for outcomes 224 from three and two phenotype categories, respectively (**Supplementary Note Table 7**). from three and two phenotype categories, respectively (**Supplementary Note Table 7**).

225

 In East Asian ancestries, ALDH2 was the most pleiotropic protein and putatively causal for 58 227 phenotypes (from 12 phenotype categories) including multiple diseases such as stroke (any
228 ischemic stroke), epilepsy, colorectal cancer, esophageal cancer, hepatic cancer, lung cancer ischemic stroke), epilepsy, colorectal cancer, esophageal cancer, hepatic cancer, lung cancer among many others. Notably, ALDH2 was not instrumented in European nor African and was uniquely instrumented in East Asian ancestry. The next most pleiotropic protein in East Asian ancestries was ABO associated with 14 phenotypes (4 phenotype categories) as expected due 232 to known pleiotropy at this locus. MLN, a small peptide hormone secreted by cells in the small
233 intestine which regulates gastrointestinal contractions and motility was causal for 10 phenotypes 233 intestine which regulates gastrointestinal contractions and motility was causal for 10 phenotypes
234 (6 phenotype categories) including cardiovascular outcomes (angina pectoris and stable angina (6 phenotype categories) including cardiovascular outcomes (angina pectoris and stable angina pectoris), gastrointestinal (chronic hepatitis B), autoimmune (rheumatoid arthritis), cancer (gastric cancer), and various biomarkers implicating its involvement in multiple biological processes and influence in a multitude of health conditions.

238

 To summarize, of our putatively causal findings, we identified many proteins influencing traits or 240 diseases in the same categories revealing the common mechanistic interplay between specific
241 outcomes. On the contrary, many proteins also demonstrated effects on various traits or diseases outcomes. On the contrary, many proteins also demonstrated effects on various traits or diseases 242 that may not be directly linked to each other, underscoring the complexity of protein functions and the intricate network of biological pathways involved in health and disease. For instance, a higher genetically predicted level of MST1 decreased the risk of IBD and its subtypes including both Crohn's disease and ulcerative colitis. This protective effect is likely due to MST1's role in modulating immune responses and inflammation, which are central to the pathogenesis of these 247 conditions. Meanwhile, increased MST1 was associated with adverse cardiovascular outcomes
248 including higher risk of coronary artery disease. In the context of IBD, MST1 may enhance 248 including higher risk of coronary artery disease. In the context of IBD, MST1 may enhance
249 mucosal healing and modulate inflammatory pathways, contributing to its protective effects. 249 mucosal healing and modulate inflammatory pathways, contributing to its protective effects.
250 Conversely, the impact of MST1 on the cardiovascular system may involve mechanisms related 250 Conversely, the impact of MST1 on the cardiovascular system may involve mechanisms related
251 to vascular inflammation and endothelial function, leading to increased blood pressure and 251 to vascular inflammation and endothelial function, leading to increased blood pressure and
252 atherosclerosis, highlighting the importance of understanding context-specific regulation of these 252 atherosclerosis, highlighting the importance of understanding context-specific regulation of these
253 potential targets. potential targets.

254 **Supplementary Note 5A:** *Validating cardiovascular related putatively causal protein-phenotype* 255 *pairs from prior studies in European ancestries*

256

257 We validated many previously known findings for cardiovascular phenotypes in European
258 ancestries (Fig. 4a and Supplementary Figure 2a). For instance, COL6A3 (SomaScan aptamer: 258 ancestries (**Fig. 4a** and **Supplementary Figure 2a**). For instance, COL6A3 (SomaScan aptamer: 259 11196-31, Olink assay: OID20292) was positively associated with coronary artery disease (CAD) 260 in all four European ancestry cohorts. This effect is concordant with our previous extensive work 261 on COL6A3⁵. In addition, we replicated previously reported findings of MMP12 on stroke by Sun 262 et al. 6 that was also further validated by Zheng et al. 7 who extended to stroke subtypes. Similar 263 to Zheng's study, European ancestry MMP12 pQTLs from deCODE and UKB-PPP were 264 associated with lower risk of any ischemic stroke (deCODE: OR = 0.92, 95% CI: 0.89–0.95, *P =* 265 1.9 × 10⁻⁷, PP_{max} = 0.98; UKB-PPP: OR = 0.92, 95% CI: 0.90–0.95, *P* = 1.9 × 10⁻⁷, PP_{max} = 1) and 266 large artery stroke (deCODE: OR = 0.77, 95% CI: 0.70–0.86, *P* = 6.0 × 10⁻⁷, PP_{max} = 1; UKB-PPP: 267 OR = 0.79, 95% CI: 0.72–0.87, $P = 6.0 \times 10^{-7}$, $PP_{\text{max}} = 0.99$).

268

269 Additionally, ITIH4 was shown in a prior study using mouse lines and colocalization to act as a 270 novel vascular smooth muscle cell-expressed gene implicated in atherosclerotic plaques⁸. 271 However, genetic evidence of causality was not determined. Here, we found a positive association 272 between ITIH4 with CAD (deCODE: OR = 1.43, 95% CI: 1.27–1.60, $P = 1.5 \times 10^{-9}$, PP_{max} = 1; Fenland: OR = 1.18, 95% CI: 1.12–1.25, *P* = 1.5 × 10⁻⁹, PP_{max} = 1), pulse pressure (deCODE: β
274 = 1.46, 95% CI: 1.00–1.93, *P* = 5.5 × 10⁻¹⁰, PP_{max} = 1; Fenland: β = 0.69, 95% CI: 0.47–0.91, *P* = = 1.46, 95% CI: 1.00–1.93, $P = 5.5 \times 10^{-10}$, PP_{max} = 1; Fenland: β = 0.69, 95% CI: 0.47–0.91, $P =$ 275 5.5×10^{-10} , PP_{max} = 0.99), and systolic blood pressure (deCODE: β = 1.66, 95% CI: 0.98–2.34, *P =* 1.8 × 10-6, PPmax = 0.97; Fenland: β = 0.78, 95% CI: 0.46–1.11, *P =* 1.8 × 10-6 276 , PPmax = 0.94), 277 consistent with and confirming the findings of earlier research using animal studies. 278

279 Interestingly, we also identified a few proteins that were protective against cardiovascular events.
280 For example, SWAP70 was protective against coronary artery disease (ARIC: OR = 0.95, 95% 280 For example, SWAP70 was protective against coronary artery disease (ARIC: OR = 0.95, 95% 281 Cl: 0.93–0.96, $P = 1.5 \times 10^{-11}$, $PP_{\text{max}} = 1$; deCODE: OR = 0.92, 95% Cl: 0.89–0.96, $P = 1.5 \times 10^{-11}$ CI: 0.93–0.96, $P = 5.7 \times 10^{-11}$, $PP_{\text{max}} = 1$; deCODE: OR = 0.92, 95% CI: 0.89–0.96, $P = 1.5 \times 10^{-11}$ 282 ⁹, PP_{max} = 0.94), small vessel stroke (deCODE: OR = 0.78, 95% CI: 0.68–0.89, P = 2.6 × 10⁻⁴, 283 PP_{max} = 0.84), and any ischemic stroke (ARIC: OR = 0.94, 95% CI: 0.92–0.97, P = 4.5 × 10⁻⁶, 284 PP_{max} = 0.98; deCODE: OR = 0.90, 95% CI: 0.86–0.95, $P = 3.0 \times 10^{-5}$, PP_{max} = 0.92). 285

286 PTN was protective against peripheral artery disease in two cohorts (Fenland: OR = 0.79, 95% 287 CI: 0.70–0.89, *P* = 7.5 × 10⁻⁵, PP_{max} = 0.97, and UKB-PPP: OR = 0.49, 95% CI: 0.37–0.65, P = 288 8.5 × 10⁻⁷, PP_{max} = 0.89), mood swings (deCODE: OR = 0.98, 95% CI: 0.97–0.99, *P* = 1.4 × 10⁻⁵, 8.5×10^{-7} , PP_{max} = 0.89), mood swings (deCODE: OR = 0.98, 95% CI: 0.97–0.99, P = 1.4 \times 10⁻⁵, 289 PP_{max} = 0.81; Fenland: OR = 0.97, 95% CI: 0.96–0.99, P = 1.4 × 10⁻⁵, PP_{max} = 0.84), and 290 anthropometric outcomes such as waist-to-hip ratio (deCODE: β = -0.04, 95% CI: -0.06, -0.03, *P* $291 = 2.3 \times 10^{-6}$, PP_{max} = 0.97; Fenland: β = -0.04, 95% CI: -0.07, -0.03, *P* = 4.0 × 10⁻⁶, PP_{max} = 0.95). 292

293 Further, DKKL1 was previously reported as putatively causal for multiple sclerosis⁹ which we also
294 found (ARIC: OR = 0.46, 95% CI: 0.37–0.58, P = 3.5 × 10⁻¹¹, PP_{max} = 1; Fenland: OR = 0.28, 95% found (ARIC: OR = 0.46, 95% CI: 0.37–0.58, *P* = 3.5 × 10⁻¹¹, PP_{max} = 1; Fenland: OR = 0.28, 95%
295 CI: 0.19–0.41, *P* = 4.3 × 10⁻¹¹, PP_{max} = 1), but here we also identified it as protective against risk CI: 0.19–0.41, $P = 4.3 \times 10^{-11}$, PP_{max} = 1), but here we also identified it as protective against risk 296 of large artery stroke (ARIC: OR = 0.59, 95% CI: 0.44–0.79, *P* = 4.2 × 10⁻⁴, PP_{max} = 0.87; Fenland: 297 OR = 0.42, 95% CI: 0.26–0.67, $P = 3.0 \times 10^{-4}$, $PP_{\text{max}} = 0.89$) as well as metabolic/endocrine 298 disorders such as hypothyroidism/myxoedema (ARIC: OR = 0.99, 95% CI: 0.98–0.99, *P =* 1.2 × 299 10^{-5} , PP_{max} = 0.95; Fenland: OR = 0.98, 95% CI: 0.97–0.99, P = 2.6 \times 10⁻⁵, PP_{max} = 0.84).

300

301
302 302 **Supplementary Note 5B:** *Validating non-cardiovascular disease related putatively causal*

303 *protein-phenotype pairs from prior studies in European ancestries*

-
- We also validated findings in other non-cardiovascular disease categories in European ancestries. Network plots for these associations are shown for autoimmune (**Supplementary Figure 2b**), neurological (**Supplementary Figure 2c**), psychiatric (**Supplementary Figure 2d**), metabolic/endocrine (**Supplementary Figure 2e**), and gastrointestinal phenotypes (**Supplementary Figure 2f**).
-
- For example, a one standard deviation increase in genetically predicted NPNT levels was 312 associated with a decreased risk of asthma which is consistent with findings in our previous work¹⁰.
- 313
314 Notably, increased levels of genetically predicted RAB21 was protective against Parkinson's 315 disease and associated with increased cognitive performance and educational attainment
316 consistent with findings of the involvement of RAB21 in neuronal development¹¹ (**Supplementary** consistent with findings of the involvement of RAB21 in neuronal development¹¹ (**Supplementary** 317 **Figure 2c**). Further, RAB21 has been implicated in obesity in concord with our findings showing **Figure 2c**). Further, RAB21 has been implicated in obesity in concord with our findings showing protective effects of RAB21 on visceral (VAT), abdominal subcutaneous (ASAT), and gluteofemoral (GFAT) adipose tissue volumes (**Supplementary Figure 2e**).
- 320
321
- INHBB has previously been implicated in serum urate levels¹² and in our analysis was found to
322 be positively associated with urate and negatively associated with estimated glomerular filtration 322 be positively associated with urate and negatively associated with estimated glomerular filtration
323 rate in all four European ancestry cohorts. In addition, we found a positive effect of genetically rate in all four European ancestry cohorts. In addition, we found a positive effect of genetically predicted INHBB levels on risk of type 2 diabetes in the UKB-PPP cohort (OR: 1.09, 95% CI: 1.04–1.13 per standard deviation (s.d.) increase in the protein level, $P = 9.8 \times 10^{-5}$, PP_{max} = 1) which had not previously been reported.
-

327
328 328 Lastly, STAT3 was positively associated with inflammatory bowel disease but negatively
329 associated with multiple sclerosis which is concordant with recent findings showing opposite 329 associated with multiple sclerosis which is concordant with recent findings showing opposite
330 effects across these two diseases¹³ and supported by an earlier randomized, placebo-controlled effects across these two diseases¹³ and supported by an earlier randomized, placebo-controlled multicenter study showing divergent outcomes of anti-TNF therapies, which are effective for 332 inflammatory bowel disease but worsen multiple sclerosis¹⁴.

 Supplementary Note 5C: *Exploratory analyses using ARIC African proteomics cohort to assess causal effects on binary cardiovascular and autoimmune-related outcomes in the Million Veteran Program*

- We identified 7 putatively causal associations for binary cardiovascular outcomes which are shown in **Supplementary Note Table 8**. The protein PCYOX1 was implicated in all diseases.
-
- **Supplementary Note 5D:** *Additional note on uniquely instrumentable proteins in East Asian ancestry and putatively causal protein-phenotype pairs from these proteins*
-
- Of the 325 unique protein-phenotype pairs identified in the Kyoto University Nagahama East Asian ancestry cohort, we found that 67 (20.6%) protein-phenotype associations were from 8
- proteins (ALDH2, ANXA7, APOA1, DDOST, GSS, PLA2G7, PRSS2, UGT1A1) specific to East
- Asian and not instrumentable by European nor African ancestries. For instance, in European
- ancestry, ALDH2 had no genome-wide significant pQTLs in ARIC, and upon LD clumping, only
- had *trans*-pQTLs in UKB-PPP, while in both Fenland and deCODE, the strict *cis*-pQTL did not

have the highest V2G score and was filtered out given the risk of horizontal pleiotropy. Similarly,

- in African ancestries, ALDH2 had no genome-wide significant pQTLs upon LD clumping.
-

An example of one association from uniquely instrumentable proteins in East Asian ancestry is

APOA1 and cholesterol levels. APOA1 was positively associated with both HDL cholesterol and

- total cholesterol levels concordant with its function as the main protein in high density
- lipoproteins mediating efflux of cholesterol. Additionally, causal effects of UGT1A1 on total
- 359 bilirubin has been previously identified in African ancestries¹⁵ and our study supports these
- findings in East Asian ancestries (β = -0.44, 95% CI: -0.46, -0.43, *P* = 1.00 × 10⁻³⁰⁰, PP_{max} = 1).
-

Supplementary Note 6: *Discordant effects across ancestries for putatively causal protein-*

phenotypes pairs

 For putatively causal associations with inconsistent MR effect estimates across ancestries, we identified 12 protein-phenotype pairs involving 9 proteins and 6 phenotypes, composed of lipid and anthropometric traits (**Supplementary Figure 3**). One pair showed discordant MR estimates across all three ancestries, four were discordant between European and African ancestries, and seven between European and East Asian ancestries. For instance, ABO was negatively associated with total cholesterol levels in Europeans but positively associated in African and East Asian ancestries. This discrepancy may require further study due to the high-impact PAV instrumental variable used for ABO in African ancestries (**Supplementary Table 15**). Similar discordance was seen with ABO and LDL cholesterol: negative in Europeans and positive in East Asian ancestries, likely due to ABO's pleiotropic nature. CD36 also showed discordant associations: positively associated with HDL cholesterol in Europeans (deCODE, Fenland, UKB- PPP) but negatively in Africans (ARIC, UKB-PPP), and negatively associated with triglycerides in Europeans but positively in Africans. The *cis*-pQTL proxying CD36 in African ancestries was a high-impact PAV. While increased CD36 typically decreases HDL and increases triglycerides, a previous study showed an inverse relationship between monocyte CD36 and HDL in African 380 ancestries¹⁶, aligning with our findings. Other discordant associations included DEF6 with height (negative in Europeans, positive in Africans) and CA4 (positive in Europeans, negative in Africans). Between European and East Asian ancestries, discordance was found for GHR and 383 AOC1 with height, APOB with LDL and total cholesterol, and ACP1 with body mass index. Notably,
384 GHR and height associations were inconsistent within European cohorts (deCODE and UKB-384 GHR and height associations were inconsistent within European cohorts (deCODE and UKB-
385 PPP), likely due to differences in proteomics platforms. PPP), likely due to differences in proteomics platforms.

 We also identified discordant effects for phenotypically related outcomes that were not exact matches and highlight an example using APOB. APOB plays a predominant role in the etiology 389 of coronary artery disease as shown in recent studies $17-19$. Likewise, our results showed that 390 APOB was positively associated with coronary artery disease (CAD) in European ancestries with 391 evidence in deCODE (β = 0.65, 95% CI: 0.51–0.80, $P = 3.4 \times 10^{-18}$, PP_{max} = 1), and Fenland (β = evidence in deCODE (β = 0.65, 95% CI: 0.51–0.80, *P* = 3.4 × 10⁻¹⁸, PP_{max} = 1), and Fenland (β = 392 0.43, 95% CI: 0.33–0.53, *P* = 2.9 × 10⁻¹⁸, PP_{max} = 1). However, APOB in East Asian ancestries 0.43, 95% CI: 0.33–0.53, $P = 2.9 \times 10^{-18}$, $PP_{\text{max}} = 1$). However, APOB in East Asian ancestries was found to be negatively associated with myocardial infarction (β = -0.08, 95% CI: -0.11, -0.05, was found to be negatively associated with myocardial infarction (β = -0.08, 95% CI: -0.11,-0.05, *P =* 1.4 × 10-8, PPmax = 1), LDL cholesterol (β = -0.06, 95% CI: -0.07, -0.05, *P =* 1.3 × 10-30 , PPmax $= 1$), HMG CoA reductase inhibitors (β = -0.14, 95% CI: -0.16, -0.12, *P* = 3.1 × 10⁻⁴⁴, PP_{max} = 1), and vasodilators used in cardiac diseases (β = -0.06, 95% CI: -0.08, -0.03, *P* = 5.0 × 10⁻⁶, PP_{max} 397 = 0.98). When querying the instruments used for APOB in European ancestries in Open Targets
398 Genetics we found that the single *cis*-pQTL proxying APOB in deCODE, rs563290, and Fenland, Genetics we found that the single *cis*-pQTL proxying APOB in deCODE, rs563290, and Fenland, rs541041, were intergenic variants (Ensembl VEP impact: Modifier). In contrast, the most severe consequence of the pQTL for APOB in East Asian ancestries, rs13306194, was missense (Ensembl VEP impact: Moderate) and could potentially be altering epitope binding rather than being a true biological signal. Nonetheless, this pQTL may still hold biological significance due to being the top hit from variant-to-gene mapping, although further investigation may be required.

 In summary, while inconsistent effects were found across ancestries for a few protein-phenotype associations we highlight that in three associations, ABO with total cholesterol levels, CD36 with HDL cholesterol levels, and CD36 with triglycerides, the protein level in African ancestries was a PAV of high impact so we advise caution in the interpretation of these results. Further, ABO is known to play a multi-faceted role in diseases and pQTLs at this locus have been associated with 410 many proteins⁶. However, since we used variant-to-gene mapping which leverages biological evidence to select instruments, these PAVs of high impact may potentially still be functionally 412 relevant. Notably, we found that decreased CD36 in African ancestries was associated with 413 increased HDL cholesterol which was consistent with findings from a previous study¹⁶. Thus, increased HDL cholesterol which was consistent with findings from a previous study¹⁶. Thus,
414 further exploration may be required with larger sample sizes to elucidate whether these findings 414 further exploration may be required with larger sample sizes to elucidate whether these findings
415 are biologically plausible. are biologically plausible.

416

Supplementary Note 7A: *Druggability of instrumentable protein-coding genes at the cohort*

- *level*
-

419
420 420 We compared instrumentable protein-coding genes against the druggable genome composed of 421 $\,$ 4,479 genes from Finan et al.²⁰ which classifies genes into Tier 1, 2, or 3 according to druggability. 4,479 genes from Finan et al.²⁰ which classifies genes into Tier 1, 2, or 3 according to druggability. Tier 1 refers to efficacy targets of approved small molecules, biotherapeutic drugs, and clinical- phase drug candidates; Tier 2 includes proteins closely associated with drug targets or linked to drug-like compounds; Tier 3 encompasses secreted or extracellular proteins, those distantly related to approved drug targets, and proteins from important druggable gene families not covered 426 in Tier 1 or Tier 2. All ancestries had proportionally comparable number of instrumentable protein-
427 coding genes in Tier 1 and 2 (**Supplementary Figure 4**). coding genes in Tier 1 and 2 (**Supplementary Figure 4**).

428
429 We found that 71, 29, and 210 proteins were shared in Tier 1, Tier 2, and Tier 3 across three ancestries, respectively (**Supplementary Figure 5**) while 26, 10, and 78 proteins were shared in Tier 1, Tier 2, and Tier 3 among all seven cohorts across three ancestries, respectively (**Supplementary Figure 6**).

-
- 434
435 **Supplementary Note 7B:** *Overlap of protein-phenotype pairs stratified by ancestry in the*
- *druggable genome and DrugBank*
-
- *7B.1 Druggable genome*

 We found that 57.7%, 78.5% and 74.2% of putatively causal protein-phenotype associations in European, African, and East Asian ancestries, respectively, overlapped with the druggable genome (**Supplementary Note Table 9**).

 7B.2. DrugBank Across ancestries, a similar proportion of proteins from the putatively causal protein-phenotype associations—33.6% in European, 35.7% in African and 35.5% in East Asian ancestry—had approved or investigational drugs available based on DrugBank21 (**Supplementary Note Tables 10–12**)**.**

-
- 449
450 **Supplementary Note 7C:** *Druggability of protein-phenotype pairs by integrating the druggable genome, DrugBank, and Open Targets Platform*
-

 We provide druggability visualization for proteins implicated in various diseases (stratified by disease category) which may be potentially explored as opportunities for drug development for European (**Supplementary Figure 7**) and East Asian ancestries (**Supplementary Figure 8**). For instance, increased genetically predicted ANGPTL4 (Tier 3 target) leads to increased risk of CAD (**Supplementary Figure 7 - Cardiovascular**).

- **Supplementary Note 8:** *Prioritization of targets for CAD and T2D*
- 460
461

 We applied filtering steps to prioritize proteins involved in CAD (**Supplementary Figure 9a**) and T2D (**Supplementary Figure 9b**). See **Supplementary Note 8 Methods** below. In European ancestries, we found directional concordance between MR estimates and hazard ratios from Cox regression for incident CAD for 18 proteins, ANGPTL4, C1R, C1S, COL6A3, COMT, DDT, 465 DUSP13, FES, FN1, IL6R, ITIH4, MST1, PCSK9, PDE5A, PLG, SCARF2, TGFB1, and TIMP2.
466 Two of these proteins. ITIH4 and ANGPTL4 were putatively causal for more than one 466 Two of these proteins, ITIH4 and ANGPTL4 were putatively causal for more than one
467 phenotype in African ancestries, albeit for different outcomes, while three proteins, IL6 phenotype in African ancestries, albeit for different outcomes, while three proteins, IL6R, PCSK9, and PLG were putatively causal for more than one phenotype in East Asian ancestries (**Supplementary Figure 9a, Supplementary Note Table 13**). We also found directional concordance between MR estimates and hazard ratios from Cox regression for incident T2D for 8 proteins, ACE, ANGPTL4, INHBB, LRIG1, MINDY1, PAM, 473 PAPPA, and TFRC in European ancestries. ANGPTL4 was the only putatively causal protein from
474 this list present in African ancestries while in East Asian ancestries, three of these proteins, INHBB, 474 this list present in African ancestries while in East Asian ancestries, three of these proteins, INHBB, 475
475 LRIG1, and TFRC were putatively causal (Supplementary Figure 9b, Supplementary Note LRIG1, and TFRC were putatively causal (**Supplementary Figure 9b, Supplementary Note**

- **Table 14**).
-

 We found that, in European ancestries, each standard deviation increase in ANGPTL4 levels was associated with increased odds of incident CAD (OR = 1.17, SE = 0.016, $P = 1.89 \times 10^{-22}$) and 480 increased odds of incident T2D (OR = 1.21, SE = 0.023, $P = 4.02 \times 10^{-17}$). These results are 480 increased odds of incident T2D (OR = 1.21, SE = 0.023, $P = 4.02 \times 10^{-17}$). These results are 481 consistent with our findings from MR, where increased circulating ANGPTL4 levels were 481 consistent with our findings from MR, where increased circulating ANGPTL4 levels were
482 associated with increased risk of CAD and T2D. Notably, MR estimates in African ancestries for associated with increased risk of CAD and T2D. Notably, MR estimates in African ancestries for ANGPTL4 also supported this concordance in European ancestries with ANGPTL4 being negatively associated with high density lipoprotein cholesterol levels and positively associated with triglycerides supporting ANGPTL4 as a potential therapeutic target for intervention.

486
487

487 In addition, each standard deviation increase in INHBB levels was associated with a 1.19-fold
488 increased hazard of T2D (SE = 0.022, $P = 3.63 \times 10^{-14}$), aligning with MR findings of increased increased hazard of T2D (SE = 0.022 , $P = 3.63 \times 10^{-14}$), aligning with MR findings of increased T2D risk. MR evidence in East Asian ancestries showed that higher genetically predicted INHBB levels increase the risk of blood urea nitrogen and G-glutamyl transpeptidase, both linked to T2D risk. However, in East Asian ancestries, reducing INHBB levels might lower HDL cholesterol and raise LDL cholesterol, potentially increasing cardiovascular risk. Thus, therapeutic strategies targeting INHBB must be carefully evaluated for adverse lipid profile effects. Comprehensive 494 research is needed to ensure benefits outweigh risks and to develop strategies that selectively
495 modulate INHBB without harming cardiovascular health. modulate INHBB without harming cardiovascular health.

496
497 We found corroborative evidence of causality between ANGPTL4 and coronary artery disease and type 2 diabetes which was validated through observational association analyses on incident coronary artery disease and incident type 2 diabetes risk in European ancestries. Additionally, through MR we also identified similar causal roles for ANGPTL4 in African ancestries for related biomarkers such as HDL cholesterol and triglycerides which were in directions congruent with our CAD and T2D findings. ANGPTL4 is an inhibitor of lipoprotein lipase (LPL) which leads to 503 increased triglyceride levels and prior studies have shown that the ANGPTL4 coding variant E40K
504 has been associated with lower plasma triglyceride levels²² and lower risk of both CAD and T2D²³. has been associated with lower plasma triglyceride levels²² and lower risk of both CAD and $T2D^{23}$. While no current therapies exist for ANGPTL4, a closely related protein ANGPTL3, which also inhibits LPL does and is targeted by zodasiran, an RNA interference therapy. Zodasiran targets ANGPTL3 expression in the liver and demonstrated efficacy in reducing triglyceride levels in 508 patients with mixed hyperlipidemia²⁴. Mechanistically, ANGPTL4 and ANGPTL3 act differently. Whereas ANGPTL3 inhibitory activity on LPL is hindered through binding to heparin, ANGPTL4

 is unaffected by heparin binding suggesting that ANGPTL4 may employ distinct regulatory mechanisms in modulating LPL activity, potentially involving alternative molecular interactions or 512 structural characteristics that confer resistance to heparin inhibition. Further research into these
513 mechanisms could unveil novel therapeutic strategies for managing cardiovascular diseases. mechanisms could unveil novel therapeutic strategies for managing cardiovascular diseases.

-
-

Supplementary Note 8 Methods

8.1. Prioritizing targets for CAD and T2D

519 For European protein-phenotype associations, we first subsetted to those with consistent MR
520 feffect across all four cohorts (ARIC, deCODE, Fenland, and UKB-PPPP) then integrated Cox effect across all four cohorts (ARIC, deCODE, Fenland, and UKB-PPPP) then integrated Cox 521 regression effects and determined directional concordance between MR effect estimates and
522 observational association estimates. Those with discordance between the two estimates were observational association estimates. Those with discordance between the two estimates were removed and the remaining proteins were retained as potential candidates. We performed this procedure for both incident CAD and incident T2D. A detailed flow diagram is shown in **Supplementary Figure 9**.

526
527

527 We highlight that when comparing the direction of MR effect estimates with observational
528 association estimates, we removed proteins with inconsistent direction and those which di 528 association estimates, we removed proteins with inconsistent direction and those which did not
529 have an observational association estimate. Since Cox regression was performed on the UKBhave an observational association estimate. Since Cox regression was performed on the UKB- PPP Olink Explore 3072 proteins, MR effect estimates from SomaScan v4 proteins would not have a corresponding observational association estimate meaning proteins exclusive to

532 SomaScan v4 were not considered. Therefore, only proteins from Olink or common proteins
533 between SomaScan and Olink were analyzed in this analysis.

- between SomaScan and Olink were analyzed in this analysis.
- *8.2. Observational associations between circulating protein abundances and incident CAD and T2D in the UK Biobank*
- We assessed whether MR effect estimates were in alignment with observational associations as this can provide an additional source of evidence supporting the purported protein-phenotype association. To perform observational association analysis on incident CAD and T2D, we used individual level data from the UK Biobank to determine whether circulating protein abundances were able to predict future risk of these diseases based on 10 years of follow-up.
-

542
543 543 CAD was defined as in our previous study⁵. Briefly, we used three criteria: (i) a record of ICD-10
544 codes I20-I25 (ischemic heart disease). (ii) an operation record of percutaneous transluminal codes I20-I25 (ischemic heart disease), (ii) an operation record of percutaneous transluminal coronary angioplasty (PTCA) or coronary artery bypass grafting (CABG), and (iii) a death record associated with ICD-10 codes I20-I25. The time to event was determined by subtracting the event registration date from the enrollment date (data field: 53), focusing on events occurring within 10 years of enrollment. We excluded individuals with pre-existing CAD who met these criteria prior to enrollment, as well as those without a recorded event date. Controls were defined as individuals 550 without a CAD record based on doctor diagnosis (data field: 6150), self-reported heart attack
551 (data field: 20002), or an ICD-10 record of I20-I25. (data field: 20002), or an ICD-10 record of I20-I25.

552
553

T2D was defined using ICD-10 code E-11 while controls were defined as individuals without any type of diabetes based on self-reports.

 We used Cox proportional hazards models (function: coxph()) adjusting for age, sex, BMI, 557 recruitment center, time to Olink processing, batch, and the first 10 principal components to
558 associate 2,922 Olink 3072 Explore platform proteins from 4,750 cases with incident CAD and 558 associate 2,922 Olink 3072 Explore platform proteins from 4,750 cases with incident CAD and
559 32,565 controls and 3,066 cases with incident T2D and 37,453 controls. Protein levels were 32,565 controls and 3,066 cases with incident T2D and 37,453 controls. Protein levels were inverse rank normal transformed prior to analysis.

Supplementary Note 9: *Detailed description of Kyoto University Nagahama East Asian cohort*

562
563

9.1. Study Cohort

 Whole-genome sequencing (WGS) and proteome analysis were conducted using samples from the Nagahama Prospective Genome Cohort for Comprehensive Human Bioscience (Nagahama Study). A subset of 2,000 individuals (1,392 women, mean age 56.7 years; 608 men, mean age 62.0 years) was selected from 8,559 participants in the first follow-up health check (2012-2016). 568 Ethical approval was obtained from the Kyoto University Graduate School of Medicine and the 569 Nagahama Municipal Review Board (No. 278). All participants provided written informed Nagahama Municipal Review Board (No. 278). All participants provided written informed consent.

9.2. Plasma Samples and Protein Quantification

- Plasma was isolated from EDTA-treated blood by centrifugation and stored at −80 °C. Protein levels were measured using SomaScan assay v4, targeting 4,740 unique proteins with 5,284 575 SOMAmers. After quality control, 1,997 plasma samples and 4,392 SOMAmers (4,196 proteins)
576 vere retained. Data were normalized and used for protein quantitative trait locus (pQTL) 576 were retained. Data were normalized and used for protein quantitative trait locus (pQTL)
577 analysis. Some proteins had multiple SOMAmers targeting different forms, distinguished analysis. Some proteins had multiple SOMAmers targeting different forms, distinguished by annotations in the SomaId and Target columns.
-

9.3. Whole-Genome Sequencing

- WGS was performed on 1,573 samples using Illumina platforms and 385 samples using a 582 DNBSEQ-G400 instrument, following standard protocols (GATK and DRAGEN). After quality
583 control, including kinship analysis and variant concordance checks, 1,823 samples and 583 control, including kinship analysis and variant concordance checks, 1,823 samples and
584 4,642,253 variants were retained for protein association analysis. 4,642,253 variants were retained for protein association analysis.
-
- *9.4. pQTL Analysis*
- 587 Genetic associations with 4,392 SOMAmers were analyzed using PLINK (v.2.00a3LM) with age,
588 sex, variant-calling pipeline, and the first five genetic principal components as covariates. The 588 sex, variant-calling pipeline, and the first five genetic principal components as covariates. The 589 genome-wide significance threshold was set at 1.08 x 10-8 after Bonferroni correction. genome-wide significance threshold was set at 1.08 × 10−8 after Bonferroni correction.
- 590
591
- *9.5. Linkage Disequilibrium (LD) Clumping*
- 592 LD clumping was performed using PLINK, defining clumping regions as 500 kb around index 593 variants with an LD threshold of $R^2 \ge 0.8$. Each region was assigned a unique ID. variants with an LD threshold of $R^2 \ge 0.8$. Each region was assigned a unique ID.
-
- *9.6. Conditional Analysis*
- 596 Independent signals at the loci were identified through stepwise selection in GCTA-COJO with
597 the following parameters: --maf 0.01 --coio-slct. --coio-collinear 0.9 --coio-p 5e-8
- the following parameters: --maf 0.01 --cojo-slct, --cojo-collinear 0.9 –cojo-p 5e-8
-
-
-

Supplementary Note 10: *Detailed description of PWCoCo and SharePro*

602
603

We performed colocalization analyses using PWCoCo and SharePro as complementary methods to safeguard against potential putative causal associations confounded by LD and ensure higher confidence in our findings. Since differences in LD structures between populations under study can introduce bias in MR analyses, the presence of a shared causal variant between the exposure and outcome can help mitigate this issue and increase the robustness of the MR findings.

608
609

10.1. Pairwise conditional and colocalization analysis (PWCoCo)

 Pairwise conditional and colocalization analysis (PWCoCo) [\(https://github.com/jwr-git/pwcoco\)](https://github.com/jwr-git/pwcoco) 612 integrates methods from conditional analyses $(GCTA-COJO)^{25}$ and colocalization analyses (coloc)²⁶ which relaxes the simplified single causal variant assumption of coloc thereby allowing the assessment of whether multiple causal variants exist and colocalize within a region. Through 615 conditional analyses, independent signals from both traits (here protein GWAS and outcome
616 GWAS) can be identified and colocalization can be conducted on each pair of conditionally GWAS) can be identified and colocalization can be conducted on each pair of conditionally independent signals for the two GWAS while upholding the strict single variant assumption of coloc. PWCoCo has been shown to outperform existing methods in scenarios where the single 619 variant assumption is violated²⁷. It also enables the identification of previously missed disease- causing variants through its ability to perform independent colocalization of secondary signals 621 and offers key improvements through its computational efficiency and ease-of-use. We performed 622 PWCoCo using default settings and set the maximum number of causal variants in the region, k , PWCoCo using default settings and set the maximum number of causal variants in the region, *k*, 623 to 5. PWCoCo, similar to coloc, reports five colocalization probabilities: H0 – no association with 624 either trait; H1 – association with trait 1, not with trait 3, not with trait either trait; H1 – association with trait 1, not with trait 2; H2 – association with trait 2, not with trait 1; H3 – association with trait 1 and trait 2, two independent SNPs; H4 – association with trait 1 and trait 2, one shared SNP (i.e., the probability that both traits are associated through the sharing of a single causal variant). We considered the maximum H4 posterior probability (PPH4) across 628 all tested pairs of conditionally independent signals and report evidence of colocalization if the 629 maximum PPH4 \geq 0.8. We note that this is different from PP_{max} used in the main text which we 629 maximum PPH4 ≥ 0.8. We note that this is different from PP_{max} used in the main text which we 630 use to denote the maximum PP between PWCoCo and SharePro colocalization methods. use to denote the maximum PP between PWCoCo and SharePro colocalization methods.

 10.2. Shared sparse Projection for colocalization analysis (SharePro)

 Shared sparse Projection for colocalization analysis (SharePro) [\(https://github.com/zhwm/SharePro_coloc\)](https://github.com/zhwm/SharePro_coloc) is a novel colocalization method which extends upon the coloc framework. SharePro uses an efficient variational inference algorithm that leverages LD 637 modelling and integration with colocalization assessment through grouping of correlated variants
638 into effect groups to accurately estimate posterior colocalization probabilities which together 638 into effect groups to accurately estimate posterior colocalization probabilities which together
639 overcome the aforementioned limitations. Further, SharePro has increased power for identifying overcome the aforementioned limitations. Further, SharePro has increased power for identifying biologically plausible signals in simulation analyses, outperforming coloc and PWCoCo while 641 maintaining low computational cost and a low false positive rate²⁸. We used SharePro ($v.5.0.0$) default settings which sets the maximum number of causal variants in the region, K, to 10.

 We emphasize that for SharePro, when K is larger than the true number of causal variants, it 645 consistently provides adequate results in comparison to setting K to the true number of causal 646 variants. Namely, K = 10 should always yield results similar to, or better than K = 5 which was set variants. Namely, $K = 10$ should always yield results similar to, or better than $K = 5$ which was set in PWCoCo due to the COJO step requiring a substantial increase in computational time with a larger defined K, which is not the case in SharePro.

 For the required LD input files to SharePro, we used the UKB 50k reference panel for European, the HGDP + 1kGP reference panel for African, and the 1kGP East Asian reference panel for East 652 Asian ancestries similar to what we utilized at the LD clumping stage previously described. 653 SharePro reports the "share" column (colocalization probabilities) for all effect groups, and we
654 reported evidence of colocalization for the protein GWAS and outcome GWAS pair if the 654 reported evidence of colocalization for the protein GWAS and outcome GWAS pair if the 655 maximum colocalization probability of any effect group was > 0.8 . We also note that this is 655 maximum colocalization probability of any effect group was > 0.8 . We also note that this is 656 different from PP_{max} used in the main text which we use to denote the maximum PP between 656 different from PP $_{max}$ used in the main text which we use to denote the maximum PP between 657 PWCoCo and SharePro colocalization methods. PWCoCo and SharePro colocalization methods.

658

Supplementary Note 11:

STROBE-MR checklist of recommended items to address in reports of Mendelian randomization studies¹ ²

Note: Page number will be added at the proof-reading stage.

This checklist is copyrighted by the Equator Network under the Creative Commons Attribution 3.0 Unported (CC BY 3.0) license.

1. Skrivankova VW, Richmond RC, Woolf BAR, Yarmolinsky J, Davies NM, Swanson SA, et al. Strengthening the Reporting of Observational Studies in Epidemiology using Mendelian Randomization (STROBE-MR) Statement. JAMA. 2021;under review.

2. Skrivankova VW, Richmond RC, Woolf BAR, Davies NM, Swanson SA, VanderWeele TJ, et al. Strengthening the Reporting of Observational Studies in Epidemiology using Mendelian Randomisation (STROBE-MR): Explanation and Elaboration. BMJ. 2021;375:n2233.

Supplementary Figure 1. Within-ancestry *cis***-pQTL effect size concordance.**

Cis-pQTL effect size concordance for (a) European and (b) African ancestry cohorts. In European and African ancestry proteomics cohorts, the effect allele of *cis*-pQTLs in each cohort was aligned to the minor allele of the corresponding variant in their respective reference panels—UKB 50k for European and HGDP+1kGP for African ancestry—to harmonize alleles across each ancestral cohort for plotting. Red line is the diagonal while blue line is the best-fit line with standard errors shown by blue shading. Horizontal and vertical gray dashed lines show $y = 0$ and $x = 0$, respectively.

(a) European ancestry cohorts pairwise comparison

(b) African ancestry cohorts pairwise comparison

Supplementary Figure 2. Protein-phenotype network plots for other phenotypes in European ancestry; six phenotype categories)

Significant estimates between proteins (orange circles) and traits (green rectangles). Arrow thickness indicates how often a protein measurement has a causal effect on the outcome trait. For simplicity, we only depict protein-phenotype pairs in which all European cohorts showed concordant direction of effect estimates. Red arrows indicate a positive causal estimate of the protein on the outcome while blue arrows indicate a negative causal estimate of the protein on the outcome.

- a. Cardiovascular (binary traits only)
- b. Autoimmune
- c. Neurological
- d. Psychiatric
- e. Metabolic/endocrine
- f. Gastrointestinal

We note the following:

- Eczema appears in both Autoimmune and Skin network plots
- Type 1 diabetes appears in both Autoimmune and Metabolic/endocrine network plots
- Inflammatory bowel disease, Ulcerative colitis, Crohn's disease, and Celiac disease appear in both Autoimmune and Gastrointestinal network plots

b. Autoimmune

e. Metabolic/endocrine

IL10RA

Ulcerative colitis FAM172A

ZPR1

IL12RB1

SCGN

Supplementary Figure 3. Protein-phenotype pairs with discordant direction across ancestries. Protein-phenotype associations that have an estimated causal effect (FDR < 0.05), passed MR sensitivity analyses, and colocalized (PP.H4 > 0.8) in either PWCoCo or SharePro but had inconsistent direction of MR effect estimates across ancestries. Sample sizes for each outcome can be found in Supplementary Tables 13, 14, and 15 for European, African, and East Asian ancestries, respectively.

Supplementary Figure 4. The overlap between instrumentable protein-coding genes and the druggable genome from Finan et al.

The number of proteins classified into each tier when normalized by the number of instrumentable protein coding genes.

Supplementary Figure 5. UpSet plot showing the overlap between instrumentable proteins and the druggable genome

nstrumentable proteins per cohort

Supplementary Figure 7. European ancestry druggability heatmaps for 12 disease categories.

In the following supplementary figures, we show druggability heatmaps for different disease categories in European ancestries.

Cell color displays the MR effect estimate based on Z score averaged across cohorts capped at -10 to +10 with red showing a positive Z score indicating a positive MR effect of the protein on the phenotype and blue showing a negative Z score indicating a negative MR effect of the protein on the phenotype. For simplicity, in European ancestries, we only display protein-phenotypes with consistent effect across European cohorts. The y-axis shows the three drug databases. DrugBank (yellow square): DrugBank shows whether the protein has an available drug in the database. OpenTargets (pink square): Open Targets Platform shows whether the protein has available clinical trial information. Druggability: The druggable genome (as defined by Finan et al.) is shown for Tiers 1 (dark green, representing efficacy targets of approved small molecules and biotherapeutic drugs), Tier 2 (dark purple, representing proteins closely related to approved drug targets or which have associated drug-like compounds), Tier 3 (light purple, representing secreted or extracellular proteins, those distantly related to approved drug targets, and members of important druggable gene families not covered in Tier 1 or Tier 2), and Unclassified (gray, all other proteins not in Tiers 1 to 3). Proteins on the y-axis within each are sorted based on the number of supported databases.

In total, for Europeans, we assessed 15 different disease categories.

However, here, we only show heatmaps for 12 disease categories and we do not show the following 3 disease categories:

- Anthropometry, due to the sheer size
- Biomarker, due to the sheer size and
- Reproductive and urogenital system, since there was only a single association.

The remaining 12 disease categories are as follows:

- 1. Cardiovascular
- since Figure 7 already shows Tier 1 and Tier 2 for Cardiovascular diseases, we show Cardiovascular Tier 3 and Cardiovascular Unclassified here.
- 2. Autoimmune
- We show the entire Autoimmune heatmap here (including Tier 3 and Unclassified) while Figure 7 only shows Tier 1 and Tier 2 for Autoimmune diseases.

For the remaining diseases, we do not stratify by druggability tier and show all protein-phenotypes together in the heatmaps.

- 3. Renal
- 4. Respiratory
- 5. Metabolic/endocrine
- 6. Neurological
- 7. Psychiatric
- 8. Musculoskeletal
- 9. Gastrointestinal
- 10. Miscellaneous
- 11. Eye

12. Cancer (all cancers are grouped together for simplicity which encompasses the following) Cancer/Skin Cancer/Metabolic disease

Cancer Cancer/Respiratory

Cancer/Neurological and psychiatric

Cancer/Gastrointestinal

Cancer/Renal

1. Cardiovascular Tier 3 (Left) and Cardiovascular Unclassified (Right)

10

5

 $\,0\,$

 -5

 -10

Type

 \vert No

No

Renal

DrugBank

Yes

No

Yes

No

OpenTargets

Druggability

Tier 1

Tier 2

Tier 3

Unclassified

9. Gastrointestinal 10. Miscellaneous

5 **Type** Type Gastrointestinal NFKB1 SULT2A1 $\mathsf{O}\xspace$ **DrugBank** $CD28$ Yes **No** APOH -5 SERPINA1 **OpenTargets** RNASE4 **Yes** -10 SCPEP1 $N₀$ EFEMP1 **Druggability** MST1 Tier 1 **KITLG** Tier₂ **PIGR** Tier₃ **11. Eye**

11. Eye 11. Eye 11. Eye 11. Experiment of the contract of the contr BTN3A2 Unclassified

Supplementary Figure 8. East Asian ancestry druggability heatmaps for 11 disease categories.

In the following supplementary figures, we show druggability heatmaps for East Asian disease categories. Cell color displays the MR effect estimate based on Z score averaged across cohorts capped at -10 to +10 with red showing a positive Z score indicating a positive MR effect of the protein on the phenotype and blue showing a negative Z score indicating a negative MR effect of the protein on the phenotype. For simplicity, in European ancestries, we only display proteinphenotypes with consistent effect across European cohorts. The y-axis shows the three drug databases. DrugBank (yellow square): DrugBank shows whether the protein has an available drug in the database. OpenTargets (pink square): Open Targets Platform shows whether the protein has available clinical trial information. Druggability: The druggable genome (as defined by Finan et al.) is shown for Tiers 1 (dark green, representing efficacy targets of approved small molecules and biotherapeutic drugs), Tier 2 (dark purple, representing proteins closely related to approved drug targets or which have associated drug-like compounds), Tier 3 (light purple, representing secreted or extracellular proteins, those distantly related to approved drug targets, and members of important druggable gene families not covered in Tier 1 or Tier 2), and Unclassified (gray, all other proteins not in Tiers 1 to 3). Proteins on the y-axis within each are sorted based on the number of supported databases.

In total, for East Asians, we assessed 14 different disease categories.

However, here, we only show heatmaps for 11 disease categories and we do not show the following 3 disease categories:

- Renal, since there was only a single association.
- Eye, since there was only a single association.
- Autoimmune, since the heatmap for all proteins is already shown in Figure 8.

For the remaining diseases, we do not stratify by druggability tier and show all protein-phenotypes together in the heatmaps. All diseases are shown separately except for Neurological and Psychiatric which we group together in one heatmap for simplicity. The remaining 11 disease categories are as follows:

- 1. Cardiovascular
- We show the entire Cardiovascular heatmap here (including Tier 3 and Unclassified) while Figure 8 only shows Tier 1 and Tier 2 for Cardiovascular diseases.
- 2. Respiratory
- 3. Metabolic/endocrine
- 4. Neurological+Psychiatric (shown together for simplicity)
- 5. Gastrointestinal
- 6. Miscellaneous
- 7. Cancer
- 8. Haematology
- 9. Anthropometry
- 10. Biomarker

1. Cardiovascular 2. Respiratory

5. Gastrointestinal 6. Miscellaneous

3. Metabolic/endocrine 4. Neurological and Psychiatric (shown together for simplicity)

7. Cancer

8. Haematology

Supplementary Figure 9. Prioritizing proteins for coronary artery disease and type 2 diabetes.

Flow diagram showing filtering steps for MR estimates and Cox regression observational estimates to identify potential targets for (a) coronary artery disease and (b) type 2 diabetes. CAD = coronary artery disease; OR = odds ratio; T2D: Type 2 diabetes.

Supplementary Note-only References

- 1. Burgess, S., Davies, N. M. & Thompson, S. G. Bias due to participant overlap in two-sample
- Mendelian randomization. *Genetic Epidemiology* **40**, 597–608 (2016).
- 2. Yuan, S. *et al.* Plasma proteins and onset of type 2 diabetes and diabetic complications:
- Proteome-wide Mendelian randomization and colocalization analyses. *Cell Reports Medicine*
- **4**, 101174 (2023).
- 3. High-Throughput Characterization of Blood Serum Proteomics of IBD Patients with Respect
- to Aging and Genetic Factors | PLOS Genetics.
- https://journals.plos.org/plosgenetics/article?id=10.1371/journal.pgen.1006565.
- 4. Identification of Common and Rare Genetic Variation Associated With Plasma Protein Levels
- Using Whole-Exome Sequencing and Mass Spectrometry | Circulation: Genomic and
- Precision Medicine. https://www.ahajournals.org/doi/10.1161/CIRCGEN.118.002170.
- 5. Yoshiji, S. *et al.* COL6A3-derived endotrophin mediates the effect of obesity on coronary
- artery disease: an integrative proteogenomics analysis. 2023.04.19.23288706 Preprint at
- https://doi.org/10.1101/2023.04.19.23288706 (2023).
- 6. Sun, B. B. *et al.* Genomic atlas of the human plasma proteome. *Nature* **558**, 73–79 (2018).
- 7. Zheng, J. *et al.* Phenome-wide Mendelian randomization mapping the influence of the
- plasma proteome on complex diseases. *Nat Genet* **52**, 1122–1131 (2020).
- 8. Ravindran, A. *et al.* Translatome profiling reveals Itih4 as a novel smooth muscle cell–specific
- gene in atherosclerosis. *Cardiovascular Research* cvae028 (2024) doi:10.1093/cvr/cvae028.
- 9. Koprulu, M. *et al.* Proteogenomic links to human metabolic diseases. *Nat Metab* **5**, 516–528 (2023).
- 10. Yoshiji, S. *et al.* Proteome-wide Mendelian randomization implicates nephronectin as an
- actionable mediator of the effect of obesity on COVID-19 severity. *Nat Metab* **5**, 248–264
- (2023).
- 11. Peralta Cuasolo, Y. M. *et al.* The GTPase Rab21 is required for neuronal development and migration in the cerebral cortex. *Journal of Neurochemistry* **166**, 790–808 (2023).
- 12. Köttgen, A. *et al.* Genome-wide association analyses identify 18 new loci associated with serum urate concentrations. *Nat Genet* **45**, 145–154 (2013).
- 13. Lincoln, M. R. *et al.* Genetic mapping across autoimmune diseases reveals shared associations and mechanisms. *Nat Genet* **56**, 838–845 (2024).
- 14. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. TNF neutralization in MS. *Neurology* **53**, 457–457 (1999).
- 15. Chen, G. *et al.* A UGT1A1 variant is associated with serum total bilirubin levels, which
- are causal for hypertension in African-ancestry individuals. *npj Genom. Med.* **6**, 1–6 (2021).
- 16. Common CD36 SNPs reduce protein expression and may contribute to a protective
- atherogenic profile | Human Molecular Genetics | Oxford Academic.
- https://academic.oup.com/hmg/article/20/1/193/2386020.
- 17. Sniderman, A. D. *et al.* Apolipoprotein B Particles and Cardiovascular Disease: A Narrative Review. *JAMA Cardiology* **4**, 1287–1295 (2019).
- 18. Ference, B. A. *et al.* Association of Triglyceride-Lowering LPL Variants and LDL-C–
- Lowering LDLR Variants With Risk of Coronary Heart Disease. *JAMA* **321**, 364–373 (2019).
- 19. Ala-Korpela, M. The culprit is the carrier, not the loads: cholesterol, triglycerides and
- apolipoprotein B in atherosclerosis and coronary heart disease. *International Journal of*
- *Epidemiology* **48**, 1389–1392 (2019).
- 20. Finan, C. *et al.* The druggable genome and support for target identification and validation
- in drug development. *Science Translational Medicine* **9**, eaag1166 (2017).
- 21. Wishart, D. S. *et al.* DrugBank: a comprehensive resource for in silico drug discovery
- and exploration. *Nucleic Acids Research* **34**, D668–D672 (2006).
- 22. Smart-Halajko, M. C. *et al.* ANGPTL4 variants E40K and T266M are associated with lower fasting triglyceride levels in Non-Hispanic White Americans from the Look AHEAD Clinical Trial. *BMC Medical Genetics* **12**, 89 (2011).
- 23. Gagnon, E., Bourgault, J., Gobeil, É., Thériault, S. & Arsenault, B. J. Impact of loss-of-
- function in angiopoietin-like 4 on the human phenome. *Atherosclerosis* **393**, 117558 (2024).
- 24. Rosenson Robert S. *et al.* Zodasiran, an RNAi Therapeutic Targeting ANGPTL3, for
- Mixed Hyperlipidemia. *New England Journal of Medicine* **0**,.
- 25. Yang, J. *et al.* Conditional and joint multiple-SNP analysis of GWAS summary statistics
- identifies additional variants influencing complex traits. *Nat Genet* **44**, 369–375 (2012).
- 26. Giambartolomei, C. *et al.* Bayesian Test for Colocalisation between Pairs of Genetic
- Association Studies Using Summary Statistics. *PLOS Genetics* **10**, e1004383 (2014).
- 27. Robinson, J. W. *et al.* An efficient and robust tool for colocalisation: Pair-wise
- Conditional and Colocalisation (PWCoCo). 2022.08.08.503158 Preprint at
- https://doi.org/10.1101/2022.08.08.503158 (2022).
- 28. Zhang, W. *et al.* SharePro: an accurate and efficient genetic colocalization method
- accounting for multiple causal signals. *Bioinformatics* **40**, btae295 (2024).